The enrollment is slower than expected

The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.

80-90% patients of ESFT will develope disease progression during the period of local treatment (surgery or radiation). The survival has been improved in these 30 years due to chemotherapy. VCD/IE is widely used in the world for the patients with ESFT, but it is rarely used in China due to its high dosage.

Inclusion Criteria:

• Age range 10-65 years old
• Histological confirmed ESFT
• No previous therapy
• ECOG performance status less than 2
• Life expectancy of more than 12 weeks
• Normal laboratory values: hemoglobin>8.0g/dl, neutrophil>2×109/L, platelet > 80×109/L, Hb > 80×1012/L, serum creatine < 1×upper limitation of normal(ULN), serum bilirubin < 1.5×ULN, ALT and AST < 2.5×ULN

Exclusion Criteria:

• Pregnant or lactating women
• Received treatment for the disease previously
• Serious uncontrolled diseases and intercurrent infection
• The evidence of CNS metastasis and bone marrow involvement
• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
• History of allergy to the drugs in this trial
• Abnormal LVEF level